Effects of first- and second-generation tyrosine kinase inhibitor therapy on glucose and lipid metabolism in chronic myeloid leukemia patients: A real clinical problem?

Chronic myeloid leukemia; Dasatinib; Diabetes mellitus; Imatinib; Metabolic syndrome; Nilotinib; Adult; Aged; Aged, 80 and over; Anthropometry; Blood Glucose; C-Peptide; Cohort Studies; Dasatinib; Female; Glucose; Humans; Imatinib Mesylate; Insulin; Insulin Resistance; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lipid Metabolism; Male; Middle Aged; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Young Adult; Oncology